| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
FAAH (fatty acid amide hydrolase). PDP-EA is a compound that increases the amidohydrolase activity of FAAH. FAAH is a serine hydrolase that degrades fatty acid amides, including the endocannabinoid anandamide, as well as other bioactive lipid amides. By increasing FAAH activity, PDP-EA may enhance the degradation of anandamide and other fatty acid amides, thereby modulating endocannabinoid signaling and other lipid-mediated pathways. PDP-EA's mechanism of action involves the inhibition of protein tyrosine phosphatases, which are enzymes that regulate cell signaling pathways. The compound's ability to modulate FAAH activity and protein tyrosine phosphatases suggests it may have broad effects on cellular signaling and metabolism. PDP-EA is a synthetic compound that has been studied for its potential to modulate key biological functions.
|
|---|---|
| ln Vitro |
PDP-EA increases the amidohydrolase activity of FAAH in vitro. The compound's activity has been characterized in enzymatic assays measuring FAAH-mediated hydrolysis of fatty acid amide substrates. PDP-EA also inhibits protein tyrosine phosphatases, enzymes that regulate cell signaling pathways. The compound's ability to modulate FAAH activity and protein tyrosine phosphatases suggests it may have broad effects on cellular signaling and metabolism. PDP-EA has been studied for its potential therapeutic and environmental applications. Detailed quantitative activity data (IC50, EC50) are not extensively available in publicly accessible sources. PDP-EA is a valuable tool for studying FAAH biology and the role of fatty acid amides in various physiological and pathological processes.
|
| ln Vivo |
PDP-EA has been studied in vivo for its effects on FAAH activity and related pathways. The compound's ability to modulate FAAH activity and protein tyrosine phosphatases suggests it may have effects on endocannabinoid signaling, inflammation, and other physiological processes. PDP-EA has been investigated for its potential therapeutic and environmental applications. Detailed in vivo pharmacokinetic and pharmacodynamic data are limited in publicly available sources. PDP-EA is a synthetic compound that has gained attention in scientific research due to its potential to modulate key biological functions.
|
| Enzyme Assay |
FAAH activity assays are performed using recombinant FAAH enzyme or tissue homogenates. The enzyme is incubated with a fluorescent or radiolabeled substrate (e.g., anandamide or arachidonoyl amide) in assay buffer (50 mM Tris-HCl pH 7.4, 1 mM EDTA, 0.1% Triton X-100) at 37°C for 30-60 minutes. The hydrolysis product (e.g., arachidonic acid or ethanolamine) is quantified by fluorescence, scintillation counting, or LC-MS/MS. PDP-EA is serially diluted and added to the reaction mixture to assess its effects on FAAH activity. Each concentration is tested in duplicate, and activity values are calculated relative to controls. Appropriate positive controls (e.g., known FAAH inhibitors like URB597) and vehicle controls are included to validate the assay.
|
| Cell Assay |
Cellular FAAH activity is evaluated in cell lines expressing FAAH, such as HeLa or SH-SY5Y cells. Cells are cultured in appropriate media (e.g., DMEM with 10% FBS) at 37°C with 5% CO₂ and treated with PDP-EA at concentrations ranging from 0.1 to 100 μM for 1-24 hours. FAAH activity in cell lysates is measured using enzymatic assays with fluorescent or radiolabeled substrates. Fatty acid amide levels (e.g., anandamide) are quantified by LC-MS/MS or ELISA. Cell viability is assessed using MTT or LDH assays to ensure compound concentrations are non-cytotoxic. Each experiment includes vehicle controls (DMSO) and appropriate positive controls (e.g., known FAAH modulators).
|
| Animal Protocol |
In vivo studies of PDP-EA are conducted in animal models to assess its effects on FAAH activity and related pathways. The compound is administered orally or intraperitoneally at doses determined by preclinical studies. PDP-EA is formulated in appropriate vehicles (e.g., DMSO/PEG300/Tween 80). Tissue samples (e.g., brain, liver, adipose tissue) are collected for FAAH activity measurements and fatty acid amide quantification. Behavioral assessments may be conducted to evaluate effects on pain, anxiety, or other endocannabinoid-mediated behaviors. Sample sizes typically range from 6-10 animals per group.
|
| ADME/Pharmacokinetics |
Molecular Weight: 405.61. Formula: C25H43NO3. CAS No.: 861891-72-7. Appearance: Solid. IUPAC Name: N-(2-hydroxyethyl)-2-(3-pentadecylphenoxy)acetamide. SMILES: O=C(NCCO)COC1=CC=CC(CCCCCCCCCCCCCCC)=C1. Solubility: DMSO. Storage: 4°C, protect from light; In solvent at -80°C for 6 months; -20°C for 1 month. Shipping: Room temperature. PDP-EA is a compound that increases the amidohydrolase activity of FAAH.
|
| Toxicity/Toxicokinetics |
No comprehensive toxicology data are publicly available for PDP-EA. The compound is intended for research use only and has not undergone full preclinical toxicology evaluation required for clinical development. As a FAAH modulator, potential toxicities may include effects on the endocannabinoid system and related physiological processes. Standard toxicity studies would include acute toxicity assessment in rodents, repeated dose toxicity studies (14-day and 28-day), and genotoxicity screening (Ames test, micronucleus assay). PDP-EA is for research use only and not for human therapeutic use.
|
| References | |
| Additional Infomation |
PDP-EA is also known as Pdp-Ea. Its IUPAC name is N-(2-hydroxyethyl)-2-(3-pentadecylphenoxy)acetamide. PDP-EA is a compound that increases the amidohydrolase activity of FAAH (fatty acid amide hydrolase). PDP-EA's mechanism of action involves the inhibition of protein tyrosine phosphatases. PDP-EA is a synthetic compound that has gained attention in scientific research due to its potential therapeutic and environmental applications. PDP-EA is a valuable tool for studying FAAH biology and the role of fatty acid amides in various physiological and pathological processes. No clinical trials have been reported for this compound. PDP-EA is for research use only.
|
| Molecular Formula |
C25H43NO3
|
|---|---|
| Molecular Weight |
405.613827943802
|
| Exact Mass |
405.324
|
| CAS # |
861891-72-7
|
| PubChem CID |
69724031
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
581.5±40.0 °C at 760 mmHg
|
| Flash Point |
305.5±27.3 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.500
|
| LogP |
8.35
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
29
|
| Complexity |
375
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(COC1C=C(CCCCCCCCCCCCCCC)C=CC=1)NCCO
|
| InChi Key |
BIOVSNWTCKRADD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H43NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-23-17-15-18-24(21-23)29-22-25(28)26-19-20-27/h15,17-18,21,27H,2-14,16,19-20,22H2,1H3,(H,26,28)
|
| Chemical Name |
N-(2-hydroxyethyl)-2-(3-pentadecylphenoxy)acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~123.27 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.08 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4654 mL | 12.3271 mL | 24.6542 mL | |
| 5 mM | 0.4931 mL | 2.4654 mL | 4.9308 mL | |
| 10 mM | 0.2465 mL | 1.2327 mL | 2.4654 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
